Ma, Chi

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature

Lymphoma Diagnosis and TreatmentBreast Cancer Treatment Studies

Cited by 9,925

Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science

Gut microbiota and healthCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 1,508

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature

Liver Disease Diagnosis and TreatmentCancer, Lipids, and Metabolism

Cited by 766

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell

Immune cells in cancerTelomeres, Telomerase, and Senescence

Cited by 609

CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma

Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J. C., Wabitsch, S., Heinrich, S., Rosato, U., et al. (2021) · Journal of Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 151

SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases

Trehan, R., Huang, P., Zhu, X. B., Wang, X., Soliman, M., Strepay, D., Nur, A., Kedei, N., Arhin, M., Ghabra, S., et al. (2025) · Nature Communications

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 74

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 24